FI120305B - Menetelmä uuden terapeuttisesti käyttökelpoisen (S,S,S)-N-(1-[2-karboksi-3-(N2-mesyylilysyyliamino)propyyli]-1-syklopentyylikarbonyylityrosiinin kiteinen alfa-polymorfisen muodon valmistamiseksi ja menetelmässä käytettäviä välituotteita - Google Patents

Menetelmä uuden terapeuttisesti käyttökelpoisen (S,S,S)-N-(1-[2-karboksi-3-(N2-mesyylilysyyliamino)propyyli]-1-syklopentyylikarbonyylityrosiinin kiteinen alfa-polymorfisen muodon valmistamiseksi ja menetelmässä käytettäviä välituotteita Download PDF

Info

Publication number
FI120305B
FI120305B FI962322A FI962322A FI120305B FI 120305 B FI120305 B FI 120305B FI 962322 A FI962322 A FI 962322A FI 962322 A FI962322 A FI 962322A FI 120305 B FI120305 B FI 120305B
Authority
FI
Finland
Prior art keywords
compound
formula
polymorphic form
solution
nujoli
Prior art date
Application number
FI962322A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI962322A (fi
FI962322A0 (fi
Inventor
Peter Dunn
Michael Leslie Hughes
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of FI962322A publication Critical patent/FI962322A/fi
Publication of FI962322A0 publication Critical patent/FI962322A0/fi
Application granted granted Critical
Publication of FI120305B publication Critical patent/FI120305B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
FI962322A 1993-12-04 1996-06-03 Menetelmä uuden terapeuttisesti käyttökelpoisen (S,S,S)-N-(1-[2-karboksi-3-(N2-mesyylilysyyliamino)propyyli]-1-syklopentyylikarbonyylityrosiinin kiteinen alfa-polymorfisen muodon valmistamiseksi ja menetelmässä käytettäviä välituotteita FI120305B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9324931 1993-12-04
GB939324931A GB9324931D0 (en) 1993-12-04 1993-12-04 Glutaramide derivatives
EP9403750 1994-11-09
PCT/EP1994/003750 WO1995015308A1 (en) 1993-12-04 1994-11-09 Crystalline, polymorphic form of (s,s,s)-n-(1-[2-carboxy-3-(n2-mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosine

Publications (3)

Publication Number Publication Date
FI962322A FI962322A (fi) 1996-06-03
FI962322A0 FI962322A0 (fi) 1996-06-03
FI120305B true FI120305B (fi) 2009-09-15

Family

ID=10746163

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962322A FI120305B (fi) 1993-12-04 1996-06-03 Menetelmä uuden terapeuttisesti käyttökelpoisen (S,S,S)-N-(1-[2-karboksi-3-(N2-mesyylilysyyliamino)propyyli]-1-syklopentyylikarbonyylityrosiinin kiteinen alfa-polymorfisen muodon valmistamiseksi ja menetelmässä käytettäviä välituotteita

Country Status (26)

Country Link
US (1) US6180665B1 (ko)
EP (1) EP0731787B1 (ko)
JP (1) JP2701988B2 (ko)
KR (1) KR100203314B1 (ko)
CN (1) CN1068586C (ko)
AT (1) ATE175664T1 (ko)
CA (1) CA2178085C (ko)
CZ (1) CZ296428B6 (ko)
DE (1) DE69416003T2 (ko)
DK (1) DK0731787T3 (ko)
EG (1) EG20562A (ko)
ES (1) ES2128031T3 (ko)
FI (1) FI120305B (ko)
GB (1) GB9324931D0 (ko)
GR (1) GR3029590T3 (ko)
HU (1) HU225959B1 (ko)
IL (1) IL111791A (ko)
MY (1) MY115430A (ko)
NO (1) NO306714B1 (ko)
NZ (1) NZ276087A (ko)
PE (1) PE9296A1 (ko)
PL (1) PL178559B1 (ko)
RU (1) RU2131869C1 (ko)
TW (2) TW434210B (ko)
WO (1) WO1995015308A1 (ko)
ZA (1) ZA949595B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7004344B2 (en) 2000-08-29 2006-02-28 Tolko Industries Ltd. Collapsible bin
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
US6975515B2 (en) 2001-08-15 2005-12-13 Agilent Technologies, Inc. Electrical module
WO2004072040A1 (en) * 2003-02-12 2004-08-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitavastatin calcium
WO2005123702A1 (en) * 2004-06-15 2005-12-29 Pfizer Limited Neutral endopeptidase inhibitor polymorph
CN109350736A (zh) * 2018-09-20 2019-02-19 南通大学 防治运动病、梅尼埃病的药物及心房钠尿肽的医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use

Also Published As

Publication number Publication date
AU8142494A (en) 1995-06-19
EG20562A (en) 1999-08-30
IL111791A0 (en) 1995-01-24
CA2178085C (en) 2002-09-03
NO962294D0 (no) 1996-06-04
TW534901B (en) 2003-06-01
ATE175664T1 (de) 1999-01-15
PL178559B1 (pl) 2000-05-31
TW434210B (en) 2001-05-16
HU9601506D0 (en) 1996-07-29
KR960706470A (ko) 1996-12-09
PL314794A1 (en) 1996-09-30
AU684114B2 (en) 1997-12-04
ES2128031T3 (es) 1999-05-01
GB9324931D0 (en) 1994-01-26
CN1142816A (zh) 1997-02-12
CN1068586C (zh) 2001-07-18
JP2701988B2 (ja) 1998-01-21
NO306714B1 (no) 1999-12-13
MY115430A (en) 2003-06-30
WO1995015308A1 (en) 1995-06-08
ZA949595B (en) 1996-06-03
DE69416003T2 (de) 1999-05-27
DK0731787T3 (da) 1999-08-30
NO962294L (no) 1996-06-04
EP0731787B1 (en) 1999-01-13
CZ296428B6 (cs) 2006-03-15
HUT74683A (en) 1997-01-28
EP0731787A1 (en) 1996-09-18
FI962322A (fi) 1996-06-03
PE9296A1 (es) 1996-04-04
DE69416003D1 (en) 1999-02-25
KR100203314B1 (ko) 1999-06-15
IL111791A (en) 2002-09-12
US6180665B1 (en) 2001-01-30
JPH09500654A (ja) 1997-01-21
HU225959B1 (en) 2008-01-28
GR3029590T3 (en) 1999-06-30
FI962322A0 (fi) 1996-06-03
CA2178085A1 (en) 1995-06-08
NZ276087A (en) 1997-11-24
CZ160496A3 (en) 1996-11-13
RU2131869C1 (ru) 1999-06-20

Similar Documents

Publication Publication Date Title
EP2408751B1 (de) Substituierte 2-acetamido-5-aryl-1,2,4-triazolone und deren Verwendung
DE69005286T2 (de) Peptide mit tachykininantagonistischer Aktivität, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate.
RU2012556C1 (ru) Способ получения производных циклоалкилглутарамида или их фармацевтически приемлемых солей
US8772244B2 (en) Tubulin inhibitors
BG106312A (bg) Имидазоимидазоли и -триазоли като противовъзпалителни средства
BG102936A (bg) Инхибитори на протеин фарнезил трансфераза
FR2518088A1 (fr) Nouveaux derives d'aminoacides, et leur application therapeutique
HU226136B1 (en) Amino acid derivatives with improved multi-drug resistance activity, process for producing them, pharmaceutical compositions containing them and use of them
EP3466962A1 (en) Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof
FI120305B (fi) Menetelmä uuden terapeuttisesti käyttökelpoisen (S,S,S)-N-(1-[2-karboksi-3-(N2-mesyylilysyyliamino)propyyli]-1-syklopentyylikarbonyylityrosiinin kiteinen alfa-polymorfisen muodon valmistamiseksi ja menetelmässä käytettäviä välituotteita
CN118234725A (zh) 杂芳族大环醚化合物的固体形式、药物组合物及制备
CN114008058A (zh) 用于治疗癌症的cdk抑制剂的前药
HU204285B (en) Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them
CZ246697A3 (en) Proline derivatives, process of their preparation and pharmaceutical composition containing thereof
HU206729B (en) Process for producing cyclic neuroquinine antagonists and pharmaceutical compositions containing them
US20070197609A1 (en) Salts of inducible nitric oxide synthase dimerization inhibitors
KR20090108034A (ko) 티모디프레신의 제약학적으로 허용가능한 염들 및 이들의 제조 공정
EP4294789A1 (en) Compositions of essentially pure form iv of n-((r)-2,3- dihydroxypropoxy)-3,4-difluoro-2- (2-fluoro-4-iodophenylamino)- benzamide and uses thereof
JP2001506265A (ja) タンパク質ファルネシルトランスフェラーゼのシクロアルキル阻害剤
AU684114C (en) Crystalline, polymorphic form of (S,S,S)-N-(1-(2-carboxy-3-(N2--mesyllysylamino)propyl)-1-cy clopentylcarbonyl)tyrosine
EP3900706A1 (en) Systemic formulation of a pyridinone derivate for coeliac disease
EP1368032B1 (en) Excitatory amino acid receptor antagonists
CN112442010A (zh) 一类前药化合物及其在治疗癌症方面的应用
KR20000015892A (ko) 단백질 파르네실 트랜스퍼라제의 억제제
WO2006027987A1 (ja) 排尿障害の予防又は治療薬

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: PFIZER IRELAND PHARMACEUTICALS

Free format text: PFIZER IRELAND PHARMACEUTICALS

FG Patent granted

Ref document number: 120305

Country of ref document: FI

MM Patent lapsed